GlassScriptPhysician profile
Peter M Mahony
NPI 1962403303
$3,741.33
in general payments reported to CMS, 2019-2025
20 companies · $552 in 2025
The $552 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $344 · 2021: $687 · 2022: $542 · 2023: $738 · 2024: $527 · 2025: $552.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,790 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,789.92 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $625.67 | 2019-2024 | Spravato |
| Otsuka America Pharmaceutical, INC. | $610.49 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $554.91 | 2021-2025 | |
| Alkermes, INC. | $447.52 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Indivior INC. | $300.44 | 2021-2024 | Perseris |
| Allergan, INC. | $204.80 | 2019-2020 | |
| Axsome Therapeutics, INC. | $199.46 | 2022-2025 | Auvelity |
| Lundbeck LLC | $191.10 | 2019-2023 | Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.86 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $102.00 | 2019-2021 | |
| Corium, LLC | $92.44 | 2023-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $86.09 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.42 | 2021-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $32.67 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2024 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $24.46 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.10 | 2023 | Uzedy |
| Jazz Pharmaceuticals INC. | $21.82 | 2021 | |
| Bausch Health US, LLC | $17.39 | 2022 | |
| Alfasigma USA, INC. | $13.42 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Mahony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.